about
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsPolyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell/bone marrow transplantationCritical care of patients with cancer[Sepsis: new findings and developments. Update 2016].Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.CD40-activated B cells induce anti-tumor immunity in vivo.Characterization of tumor-associated B-cell subsets in patients with colorectal cancer.Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantationCD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.The use of statins in hematopoietic stem cell transplantation.The role of B cells in the pathogenesis of graft-versus-host disease.Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application.Overcoming tumor-mediated immunosuppression.Generation of human CD40-activated B cells.Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis.Murine model of CD40-activation of B cells.A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells.Regulatory B10 cells display an altered homoeostasis in acute graft-versus-host disease.Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case reportProcessing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells.Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy.Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission.[Staffing needs of an intensive care unit in consideration of applicable hygiene guidelines--an exploratory analysis].[Mortality of hematology-oncology patients with neutropenia in intensivecare].Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity.The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.Acquired Long QT Syndrome and Torsade de Pointes Associated with HIV Infection.CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants.The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2.Comment on "multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies".Complex interactions between B cells and dendritic cells.[Sepsis. Update 2012].CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.Identification of native, immunogenic peptides from Cyclin D1.Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
P50
Q24200813-84832056-D029-4A58-BC43-387CF5CA3C47Q24234072-2623CC9D-8DC6-46E8-8D89-79516E9C8D12Q26746976-D53469DE-630D-40CB-B878-923024E86A8FQ30244870-AFDB06AE-9F8B-4AD4-B0BB-7F64AA697B60Q33405002-68D0805B-4940-438C-A918-71DAF178EC98Q33709425-066E7D00-4D3B-438E-B6B1-63017645CAF2Q34103969-1BE915DA-7BDE-4D0C-BEFD-5681A000846BQ34185528-C1BD3BA1-3808-47E5-B0F5-8E0B74B3BF4BQ36833808-56EE24FE-E5BE-4C3B-B56A-F17E7C836139Q37336918-E62605D2-EAA2-4727-8AD5-65D10B62EFDBQ37509119-1975635E-89E5-4B09-BF66-750895B810BEQ37596195-2307BB44-BA5F-4B0E-8BD1-F5AACD50AD8CQ37657429-D4D3EE84-7FEB-415B-88A5-4142FD2D4473Q38096525-943D182A-7220-4B3F-BBCC-89B51349829AQ38113268-F5CA3C6E-B34C-47BD-98B2-7E6CB038E4F8Q38262255-33AFB3DD-52DF-4FCD-9FAB-740ECCA78290Q38272355-29C4A572-30B8-4FE7-AD64-7CC28D538EE3Q38325654-F90DEF7C-4C4B-4FE6-985B-261B302DBA17Q38332142-C1E47BC9-2866-4B9A-A847-AE2F86A569ECQ39117820-B786DA14-4AFC-4582-B8F1-61BD5699FE5AQ39311644-96908A3F-75D5-463C-A4B6-A56F8DAD9CC4Q39744841-A8DAF405-8C42-4F1F-A9FA-2D4D0E5EEC44Q40329387-85499FA0-F859-4F55-B3BB-967C87549BEBQ40475503-5C4D3D5E-1833-414D-B714-EF389A439DFCQ40502860-50EF806E-83CB-46F6-B2EC-B6C857BB8043Q40640735-CD755B7D-14D2-4357-BBA4-C242ADE41C81Q40777838-B819EDC0-1FE8-41F6-979C-5E1135609476Q41104932-AB4E2F2B-7DCD-46F4-B2D0-F6DD8C3A6CEFQ41212400-0135CD09-AC12-4881-BB30-77A40B51F461Q41703131-6DA0273A-B72A-4EBC-BF60-C6F0F1212FABQ41761209-99556D21-C027-4E9C-ACD0-C23969679CC8Q42430296-01A066BC-F059-4A44-9B96-CCC85A859D5CQ42742311-3A871103-F16E-46C1-B841-4EE8451699FBQ42827087-0899BC55-C19B-4F53-8D77-23B01B2F45ECQ43441054-49777E8E-9A34-4B42-96B1-0ADCC3376862Q43459489-10576CA4-261A-4BB1-AF17-49B5B5E3ED40Q44328297-CD5FDEC2-119D-4780-B1D0-BDA09F2E143CQ44330666-83A12BD6-F396-4ACD-BA13-6174ECE94D8EQ44399322-54318DE7-B8DD-420F-B072-449E8EB688B5Q44636050-A5DFDB11-1283-42A4-AA55-A7995609EC57
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexander Shimabukuro-Vornhagen
@ast
Alexander Shimabukuro-Vornhagen
@en
Alexander Shimabukuro-Vornhagen
@es
Alexander Shimabukuro-Vornhagen
@nl
type
label
Alexander Shimabukuro-Vornhagen
@ast
Alexander Shimabukuro-Vornhagen
@en
Alexander Shimabukuro-Vornhagen
@es
Alexander Shimabukuro-Vornhagen
@nl
prefLabel
Alexander Shimabukuro-Vornhagen
@ast
Alexander Shimabukuro-Vornhagen
@en
Alexander Shimabukuro-Vornhagen
@es
Alexander Shimabukuro-Vornhagen
@nl
P106
P21
P31
P496
0000-0002-2351-7294